JP2008518090A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518090A5 JP2008518090A5 JP2007539188A JP2007539188A JP2008518090A5 JP 2008518090 A5 JP2008518090 A5 JP 2008518090A5 JP 2007539188 A JP2007539188 A JP 2007539188A JP 2007539188 A JP2007539188 A JP 2007539188A JP 2008518090 A5 JP2008518090 A5 JP 2008518090A5
- Authority
- JP
- Japan
- Prior art keywords
- heparin
- medicament
- desulfated
- thrombosis
- platelet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 13
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 10
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 claims 7
- 230000010118 platelet activation Effects 0.000 claims 5
- 208000007536 Thrombosis Diseases 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 229960002897 heparin Drugs 0.000 claims 2
- 229920000669 heparin Polymers 0.000 claims 2
- 230000003113 alkalizing effect Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 239000004019 antithrombin Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 239000003805 procoagulant Substances 0.000 claims 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 230000019635 sulfation Effects 0.000 claims 1
- 238000005670 sulfation reaction Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/974,566 US7468358B2 (en) | 2004-06-16 | 2004-10-27 | Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome |
| PCT/US2005/039011 WO2006047755A2 (en) | 2004-10-27 | 2005-10-26 | Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (hit) syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008518090A JP2008518090A (ja) | 2008-05-29 |
| JP2008518090A5 true JP2008518090A5 (enExample) | 2008-12-11 |
Family
ID=36228513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007539188A Pending JP2008518090A (ja) | 2004-10-27 | 2005-10-26 | ヘパリン起因性血小板減少症（ｈｉｔ）症候群の硫酸化多糖類治療のための方法および医薬 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7468358B2 (enExample) |
| EP (1) | EP1807095B1 (enExample) |
| JP (1) | JP2008518090A (enExample) |
| AT (1) | ATE507836T1 (enExample) |
| AU (1) | AU2005299568A1 (enExample) |
| CA (1) | CA2585640C (enExample) |
| DE (1) | DE602005027883D1 (enExample) |
| ES (1) | ES2366342T3 (enExample) |
| WO (1) | WO2006047755A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050261241A1 (en) | 2004-05-19 | 2005-11-24 | Celsus Biopharmaceuticals, Inc. | Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses |
| US20090054374A1 (en) * | 2007-02-28 | 2009-02-26 | Paringenix, Inc. | Methods of treating acute exacerbations of chronic obstructive pulmonary disease |
| WO2009015183A1 (en) * | 2007-07-23 | 2009-01-29 | University Of Utah Research Foundation | Method for blocking ligation of the receptor for advanced glycation end-products (rage) |
| WO2009117677A2 (en) * | 2008-03-21 | 2009-09-24 | University Of Utah Research Foundation | Methods for controlling intracellular calcium levels associated with an ischemic event |
| US8288515B2 (en) | 2009-07-31 | 2012-10-16 | Reliable Biopharmaceutical Corporation | Process for preparing Fondaparinux sodium and intermediates useful in the synthesis thereof |
| US8420790B2 (en) | 2009-10-30 | 2013-04-16 | Reliable Biopharmaceutical Corporation | Efficient and scalable process for the manufacture of Fondaparinux sodium |
| DK3144325T3 (da) * | 2010-09-14 | 2021-01-25 | Univ Miyazaki | Heparin med høj renhed og fremstillingsfremgangsmåde dertil |
| NZ611316A (en) * | 2010-12-01 | 2014-12-24 | Univ Australian | Histone inhibition |
| WO2013016181A1 (en) * | 2011-07-22 | 2013-01-31 | Paringenix, Inc. | Compositions and methods for anti-coagulation |
| CA2862606C (en) | 2012-02-02 | 2020-08-25 | Reliable Biopharmaceutical Corporation | An efficient and scalable process for the manufacture of fondaparinux sodium |
| LT2846809T (lt) * | 2012-05-09 | 2021-01-25 | Cantex Pharmaceuticals, Inc. | Mielosupresijos gydymas |
| AU2016234916A1 (en) * | 2012-05-09 | 2016-11-17 | Cantex Pharmaceuticals, Inc. | Treatment of myelosuppression |
| US20170096549A1 (en) | 2014-03-17 | 2017-04-06 | Cantex Pharmaceuticals, Inc. | Multivalent cation formulations of partially desulfated heparins |
| US10052346B2 (en) | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
| EP3265828B1 (en) | 2015-03-03 | 2021-04-21 | Laboratory Corporation of America Holdings | Methods and systems for measuring serotonin in a sample |
| WO2019236453A1 (en) * | 2018-06-03 | 2019-12-12 | Glycomira Therapeutics, Inc. | Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and /or chemotherapy |
| WO2022015794A1 (en) | 2020-07-14 | 2022-01-20 | Optimvia, Llc | Methods for synthesizing non-anticoagulant heparan sulfate |
| GB202006960D0 (en) * | 2020-05-12 | 2020-06-24 | Aplagon Oy | Therapeutic |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668118A (en) | 1992-07-24 | 1997-09-16 | Cavalier Pharmaceuticals | Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G |
| EP0651645B1 (en) * | 1992-07-24 | 2002-02-27 | Thomas P. Kennedy | Medicament for inhibiting neutrophil elastase and cathepsin g |
| US5696100A (en) * | 1992-12-22 | 1997-12-09 | Glycomed Incorporated | Method for controlling O-desulfation of heparin and compositions produced thereby |
| US5990097A (en) * | 1996-07-29 | 1999-11-23 | Cavalier Pharmaceuticals | Methods of treating asthma with o-desulfated heparin |
| DE69930419T2 (de) | 1998-11-13 | 2006-09-07 | Eli Lilly And Co., Indianapolis | Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie |
| AU763042B2 (en) | 1999-09-13 | 2003-07-10 | Charlotte-Mecklenburg Hospital Authority | Method of inhibiting NF-kappaB with heparin |
| US6489311B1 (en) | 2000-05-02 | 2002-12-03 | Charlotte-Mecklenburg Hospital Authoirty | Method for the prevention of apoptosis |
| US20080207895A1 (en) | 2002-11-27 | 2008-08-28 | Rosenberg Robert D | Methods for synthesizing polysaccharides |
| US20050261241A1 (en) * | 2004-05-19 | 2005-11-24 | Celsus Biopharmaceuticals, Inc. | Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses |
| US20050282775A1 (en) | 2004-06-16 | 2005-12-22 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome |
-
2004
- 2004-10-27 US US10/974,566 patent/US7468358B2/en not_active Expired - Lifetime
-
2005
- 2005-10-26 DE DE602005027883T patent/DE602005027883D1/de not_active Expired - Lifetime
- 2005-10-26 EP EP05824840A patent/EP1807095B1/en not_active Expired - Lifetime
- 2005-10-26 WO PCT/US2005/039011 patent/WO2006047755A2/en not_active Ceased
- 2005-10-26 ES ES05824840T patent/ES2366342T3/es not_active Expired - Lifetime
- 2005-10-26 JP JP2007539188A patent/JP2008518090A/ja active Pending
- 2005-10-26 CA CA2585640A patent/CA2585640C/en not_active Expired - Lifetime
- 2005-10-26 AT AT05824840T patent/ATE507836T1/de not_active IP Right Cessation
- 2005-10-26 AU AU2005299568A patent/AU2005299568A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008518090A5 (enExample) | ||
| Hao et al. | Heparin: an essential drug for modern medicine | |
| CA2585640A1 (en) | Use of 2-o desulfated heparin for the treatment of heparin-induced thrombocytopenia (hit) syndrome | |
| AU2013260101B2 (en) | Treatment of myelosuppression | |
| Tavassoly et al. | Heparin-binding peptides as novel therapies to stop SARS-CoV-2 cellular entry and infection | |
| RU2010114051A (ru) | Применение grf-1(1-29) и кортиколиберина в качестве терапевтических средств | |
| RU2010113976A (ru) | Применение glp-1 в качестве терапевтического средства | |
| EP4628100A3 (en) | Anti-viral compounds and methods for administration thereof | |
| RU2010114045A (ru) | Применение пептида sfllr-oh и мурамилдипептида в качестве терапевтических средств | |
| RU2010113983A (ru) | Применение туфтсина в качестве терапевтического средства | |
| JP2012518624A5 (enExample) | ||
| RU2010114023A (ru) | ПРИМЕНЕНИЕ ПЕПТИДА Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА | |
| RU2010114030A (ru) | Применение пептида в качестве терапевтического средства | |
| JP2006518750A5 (enExample) | ||
| TWI565470B (zh) | 玻尿酸之用途及疼痛抑制用醫藥組成物 | |
| JP2017507142A5 (enExample) | ||
| JP2010530423A (ja) | 免疫活性化剤を用いたウイルス感染の早期介入 | |
| Lee et al. | Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis | |
| RU2010114019A (ru) | Минигастрин в качестве терапевтического средства | |
| JP2014504613A5 (enExample) | ||
| EP1609473A8 (en) | Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria | |
| US20170096549A1 (en) | Multivalent cation formulations of partially desulfated heparins | |
| WO2021215987A1 (en) | Compositions and methods for use in the treatment of respiratory infections | |
| CN101342185A (zh) | 连翘酯苷在制备抗肿瘤化疗增敏减毒药物或抗艾滋病增敏减毒药物中的应用 | |
| I Paraskevas et al. | Editorial [Carotid Intima-Media Thickness and Ezetimibe: The End of a Misunderstanding?] |